We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go: Extended investment: Withheld
Jewellery Discovery is a new online marketplace designed for luxury watches and jewellery. The company specialises in vintage and antique jewellery. It designs a wide range of unique and exceptional pieces available online. Each piece is authentic and checked by in-house specialists. Jewellery Discovery has more than 55,000 followers on Instagram. The company has been serving high-net-worth clients including Member of Parliament. Jewellery Discovery is seeking to drive a marketing campaign and expand its team. 
days to go: Expired investment: £30,990
Alter Vego (AV) aims to create an extensive range of plant-based, customisable supplements. The company asserts that its production process is sustainable. It starts by creating a vegan protein base blend from ingredients such as pea, hemp, quinoa and brown rice that is ethically sourced and produced. It then develops daily sachets that contain Omega 3, B12, D3, K1, digestive enzymes, and probiotics to complement the base blend. AV argues that the sachets provide 100% of a user's Recommended Dietary Allowance (RDA) over any pre-mixed bulk blend. It aspires to become a contender in the global nutrition sector worth $702 billion. AV will use the investment for manufacturing and marketing its products across the UK.

Pitch Rated

67%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £46,455
Centaur Robotics is redefining mobility for the 10% of the global population who require assistance to walk 400 meters. Representing a £7 billion global opportunity, the company offers a blend of convenient service and innovative two-wheeled vehicle design, catering to individuals and collaborating with international brands in sectors such as airlines, shopping centers, retirement living, hotels, and restaurants. After a successful 2020 investment round, Centaur Robotics is currently seeking the final £65,000 of its seed equity round. This funding will facilitate pre-production market trials, design refinements, large-scale testing, and production expansion. With established commercial traction, the company aims for a full commercial launch by June 2024.
days to go: Expired investment: £795,101
EMSOL is a collaborated, passionate, expert, professional business and local authority. It intelligently focuses on air pollution that needs to be urgently reduced. The company provides an IoT platform and sensor-based service to unlock environmental insights that enable permanent, feasible, and rapid change. EMSOL measures air and noise pollution by using the latest calibrated sensors with its clever mathematics it targets interventions to reduce pollution. The company's team is a range of committed, top-quality domain experts. The company is already working with fleet operators, local councils, and developers by generating data-led insights to act on the causes of transport pollution.
days to go: Expired investment: Withheld
Burleighs Gin is a company that aims to establish itself as the leader in the gin market. It is the official gin partner for entities such as Leicester City Football Club, Leicester Tigers RFC, and the King Richard III foundation. Burleighs plans to introduce a 'non-alcoholic gin' apart from its gin products. The company feels that this will allow Burleighs to enter into the rapidly rising 'low & no' growth sector, now valued at £60 million a year in the UK. It also intends to commission the production of a 'Ready to Drink Gin & Tonic' in a can, another growth market driven by the popularity of gin that is now worth £472 million a year. Burleighs has on-trade listings secured with Cosy Club, Loungers, All Bar One, and Miller & Carter. It has hosted consumer events during 2019 including; Picnic in the Gardens, World Gin Day festival and The Great Burleighs Express. Burleighs Gin has been featured in BBC Good Food Guide's 'Best Gins to try in 2019'. They will use 50% of the investment for new product development, 15% for distillery expansion, 15% for recruitment drives, 10% for export growth, and 10% as marketing expenses.

Pitch Rated

62%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £130,490
Better Universal Grub (BUG) aspires to make edible insects mainstream and asserts that it is a sustainable and delicious superfood. BUG's argues that its recipe kits make it easy to cook tasty insect meals at home. It will initially sell its kits Direct-To-Consumer (DTC) and expand into retail and food services by 2022. The company averaged a 30%+ Month-on-Month (MoM) growth rate of meals that it sold during its beta testing. It aims to become a contender in the estimated £1.1 billion insect protein market across the UK. The company's recipes have been showcased by celebrity Chef Prue Leith. BUG has been featured in media entities like The Guardian, The Grocer and Business Insider. It will use the investment to scale the business and begin getting its tasty grub on dinner tables across the country
days to go: Expired investment: £372,855
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph